FDA Adds Naloxone Info to Opioid Scripts

  • Post author:
  • Post category:legislation
  • Reading time:3 min(s) read

The Food and Drug Administration announced a new requirement for drugmakers to help inform consumers about naloxone. Naloxone is a drug that helps reverse opioid and other drug overdoses. The new rule means that every prescription drug containing opioids will now include information about naloxone.

The naloxone notice is just one small thing that they’re hoping will help people stay alive during the pandemic. People who are abusing opioids may not be aware that it’s an option. Many people are isolated from other drug users and staying home during the pandemic.

Overdoses Are Increasing During Pandemic

Drug overdoses are multiplying quickly during the age of COVID-19, and numbers of deaths were higher than ever in 2019 before the pandemic even touched American lives.

Public health officials have warned the public and doctors to expect significant increases in “deaths of

Continue Reading FDA Adds Naloxone Info to Opioid Scripts

AMA Says Opioid Crisis Worsened By COVID-19

The American Medical Association put out an article this week about the opioid epidemic. Just like other public health crises, opioid addiction seems to be on the backburner. Yet people who are addicted to opioids are more vulnerable to COVID-19.

In many places, both the COVID-19 crisis and the opioid epidemic are currently both causing casualties. In the state of Illinois, DuPage County has suffered 315 deaths so far this year from the novel coronavirus. But the agency also reports that there have been 303 overdoses reported in the Emergency Room this year.

Last year, 96 people overdosed on opioids. But the numbers are growing for 2020. For three weeks between April and May, the county experienced 22 fatal overdoses.

Fewer Resources For Addicted During COVID-19

Many of the people who overdosed in Dupage County were alone and practicing social …

Continue Reading AMA Says Opioid Crisis Worsened By COVID-19

Research Proves Opioid Agonists Prevent OD’s and Relapse

Using Medication-Assisted Treatment once carried stigma in the recovery community. However, recent research has shown how much these aspects of treatment can save lives. Opioid agonists keep people from relapse and overdose death.

Many people have a lack of understanding about why the drug is useful or how it helps people begin the path to recovery. This stigma can keep people from getting the help they need to stay clean and sober. This is a big gap in the recovery world, unfortunately. A lack of MAT options could mean the difference in recovery versus relapse. Researchers say that one group of MAT options, opioid antagonists, are especially effective when used by people new to recovery.

What Are Opioid Agonists?

Opioid agonists help people with heroin or prescription opioid use disorder abstain from those drugs. In recovery, doctors may prescribe these …

Continue Reading Research Proves Opioid Agonists Prevent OD’s and Relapse

Does the Dental Industry Has an Opioid Script Problem?

Recent studies show that the dental industry in America may be an essential link in the addiction crisis, with nearly half of dental prescriptions exceeding prescription guidelines for acute pain management.

The research, published today in the American Journal of Preventative Medicine, covered a five-year study period of dental prescriptions.

What Do the Numbers Say?

Dentists are a vital component in addiction prevention that has often been overlooked in research studies. However, the dental industry is responsible for 10% of all opioid prescriptions in the United States. Yet, in three out of ten prescriptions, dentists prescribed a more powerful opioid than necessary following painful procedures. And the prescriptions were typically for longer than three days, which is the current opioid prescription guideline for acute surgery pain.

For the study, the researchers analyzed data on nearly 550,000 dental visits by …

Continue Reading Does the Dental Industry Has an Opioid Script Problem?

FDA Studies On Opioid Education Were Flawed

Studies on doctor education in the opioid epidemic were flawed, and hindsight, as they say, is 20/20. And although the FDA has lobbied heavy criticism and the pharmaceutical industry has paid fines, they are not without blame. They took years to investigate the makers and distributors of Oxycontin. Instead of protecting consumers, the federal agency instead left its own bumbling paper trail for opioid education oversight, according to a New York Times report.

The FDA, documents reveal, did little to stop overprescribing and, in fact, created a study that failed to be accurate by design, according to Caleb Alexander, the senior author of the study. “It’s unclear why the FDA didn’t insist upon a more scientifically rigorous evaluation of this safety program.” This means that it’s unclear if any studies were correct.

What Studies Were Done on the Safety

Continue Reading FDA Studies On Opioid Education Were Flawed

Oxycontin Makers Sink Claws Into China

A report has come out detailing the marketing moves that Purdue Pharma, the drugmaker responsible for Oxycontin and other variations of opioid, has moved on to China. Of course, it’s no big secret that companies like food and pharmaceutical makers take their wares overseas to new markets.

What’s unusual about Purdue’s business moves is that the behavior that cost billions of dollars in US lawsuits is now being deployed in China.

Boosting Sales and Breaking Laws in China

Stat News claims that when sales began to crash due to the opioid crisis, the Sacklers and their subsidiaries set their eyes on the global market. In China, Purdue’s international pharma dealer, Mundipharma, pushed for profits over ethics without fail. While the profit scheme unraveled very publicly in the US courts, quietly, Purdue Pharma began marketing elsewhere.

Current and former employees told …

Continue Reading Oxycontin Makers Sink Claws Into China

Purdue Pharma in Planning to Settle Lawsuits with 10-12 Billion USD

Purdue Pharma, the pharmaceutical giant that makes OxyContin, and its owners, the wealthy Sackler family, are in talks to settle over 2,000 lawsuits aimed at the company for the opioid crisis. Preliminary discussions are in the range of $10 billion to $12 billion.

Which Lawsuits Are Involved?

The 2,000 lawsuits stem from cities, counties, and states that have suffered from the opioid crisis for years. The current suit in which settlement talks are being made is in Ohio. The pharmaceutical company wants to consolidate the lawsuits and have the affected parties decide who gets what in terms of settlement talks.

The lawsuit payouts are part of confidential conversations and discussed by Purdue’s lawyers at a meeting in Cleveland last Tuesday, Aug. 20, according to NBC news.

What Are the Lawsuits About?

The lawsuits point blame to Perdue Pharma and …

Continue Reading Purdue Pharma in Planning to Settle Lawsuits with 10-12 Billion USD

Did Abuse-Deterrent Oxy Work? Purdue Won’t Say

  • Post author:
  • Post category:big pharma
  • Reading time:2 min(s) read

In 2010, a reformulated version of Oxycontin was released. The pharma giant, Perdue Pharma, said the new formula would help deter abuse. The new version of the pill couldn’t be crushed, snorted or smoked. This change was expected to make it more difficult for drug abusers to misuse it. It’s been nine years since the different drug formula went into effect, and neither the government nor Purdue Pharma will release information to the public on results.

“We asked for that data probably 40 or 50 times in last four or five years and were denied every time,” Dr. Raeford Brown, whose term as an FDA adviser ended last March, recently told the Washington Post. The committee she served on is still waiting to get the numbers from either the FDA or Purdue.

New Oxy Formula May Have Caused Other Public

Continue Reading Did Abuse-Deterrent Oxy Work? Purdue Won’t Say

Italy Starts its Own Oxycontin Probe

In Italy, a peculiar rise in opioid prescriptions brought suspicion against Perdue Pharmaceuticals and a doctor named Guido Fanelli. Authorities began to suspect a conspiracy among a group of pharmaceutical executives police nicknamed “The Pain League.” Used to fighting corruption and the inner workings of criminal cases such as mob bosses, authorities sought to find culpability within Mundipharma — the international arm of Purdue Pharma. They began an investigation using wiretaps and subpoenas to follow the money.

Purdue Pharma, the manufacturer of Oxycontin, faces over 2,000 lawsuits in the United States over its role in the opioid crisis. This case is the first known case outside the U.S., where executives and employees of Perdue are criminally charged and implicated. While the opioid epidemic has cost fewer lives in Italy, the criminal intent, prosecutors say, is clear.

Making Money Promoting Opioids

Continue Reading Italy Starts its Own Oxycontin Probe

Drug Distributor McKesson Settles WV Opioid Lawsuit

McKesson, a drug distribution giant, has decided to settle a lawsuit in West Virginia with a 37 million dollar settlement. The company paid $14.5 million upon settling and will pay another $4.5 million a year for the next five years.

About the Lawsuit

The original lawsuit accused the drug distributor of turning a willfully blind eye to suspicious behavior. Many opioid distributors have been charged with ignoring abnormally large orders, such as massive amounts of pills sent to different pharmacies across the state repeatedly.

When irregularities were noted, the company did nothing to investigate.

As part of the settlement, McKesson did not have to admit any wrongdoings.

McKesson’s Ongoing Trouble

This lawsuit is not the company’s first lawsuit for its practices regarding opioids. In 2017, the McKesson paid $150 million in penalties. They were forced to suspend sales of opioids …

Continue Reading Drug Distributor McKesson Settles WV Opioid Lawsuit